|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.370 USD | +6.55% |
|
-5.79% | -12.68% |
| 05:50am | Myriad Genetics, Inc., Q2 2026 Earnings Call, Jul 30, 2026 | |
| 07-31 | Myriad Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Myriad Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,204 | 1,176 | 1,697 | 1,248 | 573.3 | 507.2 | - | - |
| Change | - | -46.65% | 44.34% | -26.46% | -54.07% | -11.53% | - | - |
| Enterprise Value (EV) | 1,864 | 1,061 | 1,595 | 1,185 | 543.6 | 507.2 | 507.2 | 507.2 |
| Change | - | -43.09% | 50.32% | -25.67% | -54.14% | -6.69% | 0% | 0% |
| P/E | -78.9x | -10.4x | -6.02x | -9.72x | -1.56x | -7.07x | -10.1x | -11.1x |
| PBR | 2.28x | 1.33x | 2.2x | 1.79x | 1.56x | - | - | - |
| PEG | - | -0x | -0x | 0.2x | -0x | 0.1x | 0.3x | 1.31x |
| Capitalization / Revenue | 3.19x | 1.73x | 2.25x | 1.49x | 0.7x | 0.59x | 0.56x | 0.54x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.59x | 0.56x | 0.54x |
| EV / EBITDA | 0x | -0x | -0x | 0x | 0x | 13.8x | 10.6x | 9.53x |
| EV / EBIT | 0x | -0x | -0x | 0x | 0x | 44.9x | 20.4x | 9.59x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.35 | -1.39 | -3.18 | -1.41 | -3.95 | -0.76 | -0.53 | -0.485 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 690.6 | 678.4 | 753.2 | 837.6 | 824.5 | 853.3 | 901.7 | 943.7 |
| EBITDA 1 | 71.9 | -21 | -6.3 | 40.4 | 38.9 | 36.81 | 47.81 | 53.23 |
| EBIT 1 | 9.1 | -32.8 | -25.5 | 21.8 | 15.1 | 11.31 | 24.84 | 52.9 |
| Net income 1 | -27.2 | -112 | -263.3 | -127.3 | -365.9 | -71.48 | -50.98 | -47.29 |
| Net Debt | -339.8 | -114.9 | -102.4 | -62.8 | -29.7 | - | - | - |
| Reference price 2 | 27.600 | 14.510 | 19.140 | 13.710 | 6.150 | 5.370 | 5.370 | 5.370 |
| Nbr of stocks (in thousands) | 79,855 | 81,034 | 88,669 | 91,035 | 93,214 | 94,448 | - | - |
| Announcement Date | 24/02/22 | 28/02/23 | 27/02/24 | 24/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.07x | - | - | -.--% | 507M | |
| -52.56x | 15.83x | -115.88x | -.--% | 20.2B | |
| 17.59x | 1.96x | 8.27x | 1.45% | 9.76B | |
| 22.82x | 4.28x | 12.13x | - | 6.58B | |
| -60.93x | 9.44x | -80.36x | -.--% | 6.28B | |
| 20.96x | 7.21x | 16.29x | 2.75% | 5.66B | |
| 163.73x | 4.09x | 26.75x | -.--% | 4.55B | |
| 19.9x | 3.52x | 10.95x | 1.9% | 4.21B | |
| 16.79x | - | - | 3.82% | 2.83B | |
| Average | 15.69x | 6.62x | -17.41x | 1.24% | 6.73B | |
| Weighted average by Cap. | -2.17x | 8.75x | -42.37x | 0.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MYGN Stock
- Valuation Myriad Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
